- Home
- News
- Articles+
- Aerospace
- Artificial Intelligence
- Agriculture
- Alternate Dispute Resolution
- Arbitration & Mediation
- Banking and Finance
- Bankruptcy
- Book Review
- Bribery & Corruption
- Commercial Litigation
- Competition Law
- Conference Reports
- Consumer Products
- Contract
- Corporate Governance
- Corporate Law
- Covid-19
- Cryptocurrency
- Cybersecurity
- Data Protection
- Defence
- Digital Economy
- E-commerce
- Employment Law
- Energy and Natural Resources
- Entertainment and Sports Law
- Environmental Law
- Environmental, Social, and Governance
- Foreign Direct Investment
- Food and Beverage
- Gaming
- Health Care
- IBC Diaries
- In Focus
- Inclusion & Diversity
- Insurance Law
- Intellectual Property
- International Law
- IP & Tech Era
- Know the Law
- Labour Laws
- Law & Policy and Regulation
- Litigation
- Litigation Funding
- Manufacturing
- Mergers & Acquisitions
- NFTs
- Privacy
- Private Equity
- Project Finance
- Real Estate
- Risk and Compliance
- Student Corner
- Take On Board
- Tax
- Technology Media and Telecom
- Tributes
- Viewpoint
- Zoom In
- Law Firms
- In-House
- Rankings
- E-Magazine
- Legal Era TV
- Events
- Middle East
- Africa
- News
- Articles
- Aerospace
- Artificial Intelligence
- Agriculture
- Alternate Dispute Resolution
- Arbitration & Mediation
- Banking and Finance
- Bankruptcy
- Book Review
- Bribery & Corruption
- Commercial Litigation
- Competition Law
- Conference Reports
- Consumer Products
- Contract
- Corporate Governance
- Corporate Law
- Covid-19
- Cryptocurrency
- Cybersecurity
- Data Protection
- Defence
- Digital Economy
- E-commerce
- Employment Law
- Energy and Natural Resources
- Entertainment and Sports Law
- Environmental Law
- Environmental, Social, and Governance
- Foreign Direct Investment
- Food and Beverage
- Gaming
- Health Care
- IBC Diaries
- In Focus
- Inclusion & Diversity
- Insurance Law
- Intellectual Property
- International Law
- IP & Tech Era
- Know the Law
- Labour Laws
- Law & Policy and Regulation
- Litigation
- Litigation Funding
- Manufacturing
- Mergers & Acquisitions
- NFTs
- Privacy
- Private Equity
- Project Finance
- Real Estate
- Risk and Compliance
- Student Corner
- Take On Board
- Tax
- Technology Media and Telecom
- Tributes
- Viewpoint
- Zoom In
- Law Firms
- In-House
- Rankings
- E-Magazine
- Legal Era TV
- Events
- Middle East
- Africa
Clifford Chance Advised on Advanced Surgical Robotics Company Edge Medical's Chapter 18A IPO and Listing in Hong Kong
Clifford Chance Advised on Advanced Surgical Robotics Company Edge Medical's Chapter 18A IPO and Listing in Hong Kong
Global law firm Clifford Chance has advised the joint sponsors and underwriters including Morgan Stanley, GF Capital, GF Securities, CICC, CLSA and CMBC Securities on the initial public offering and listing of advanced surgical robotics company Shenzhen Edge Medical Co., Ltd. (Edge Medical) on the Main Board of the Hong Kong Stock Exchange, under the Exchange's Chapter 18A Listing Rules for Biotech Companies.
The listing is expected to raise approximately HK$1.2 billion, backed by several cornerstone investors including Abu Dhabi Investment Authority, UBS, Tencent, OrbiMed and ChinaAMC (Hong Kong).
Founded in 2017 in Shenzhen, Edge Medical is an advanced surgical robotics company in the medical device industry, dedicated to designing, developing and manufacturing surgical robots for minimally invasive surgery, as well as non-invasive surgery. It is the first company in China and second globally to receive registration approvals of all of its multi-part endoscopic, single-port endoscopic and natural orifice surgical robots.
Partner Fang Liu said, "Edge Medical's listing reflects the depth of China's medtech sector, showcasing innovation in surgical robotics, as well as the strength of Hong Kong's biotech listing platform. We leverage deep biotech expertise and proven Chapter 18A experience to guide clients through every stage of these landmark listings. These transactions are vital to scaling life science breakthroughs globally and central to Hong Kong's strategy to build world class champions."
Clifford Chance is a leading advised of pharmaceutical, biotech and healthcare companies, having advised most recently on the listings of B&K Corp, Ab&B Bio-Tech and Lepu Biopharma.
The Clifford Chance team was led by Fang Liu (Partner) and Virginia Lee (Partner) led the transaction with support from Janet Fok (Counsel), Ran Bi (Senior Associates) and Ryan Ho (Senior Associates), Ruoyu Xiong (Associates) Choo Jun Kai (Associate), Phoebe Yan Ting Lo (Associate) and Grace Wang (Associate), Minting Luo (Legal Assistant), Carina Tan (Trainee Solicitor), Pascal Chan (Paralegal) and Jay Lee (Paralegal).
Click to know more about Clifford Chance
If you have a news or deal publication or would like to collaborate on content, columns, or article publications, connect with the Legal Era News Network Team and email us at info@legalera.in or call us on +91 8879634922.


